23 December 2019
An Interview with leading Endocrine Oncologist Gary Hammer MD. PhD.
Future Science Group (FSG), today has published a two-part interview with Garry Hammer, the director of the Endocrine Oncology Program at the University of Michigan Rogel Cancer Center (MI, USA), the President-Elect of the Endocrine Society and the cofounder/founder of the companies Millendo Therapeutics (NASDAQ, MLND; MI, USA) and Vasaragen (MI, USA), respectively. Both parts have been published today in the International Journal of Endocrine Oncology.
In part one of the interview, Hammer discusses the current research underway in his laboratory at the University of Michigan and how he plans to make strides in the development of novel therapeutics for rare adrenal neoplasia’s and cancers. In part two, Hammer further explains how the Endocrine Oncology Program at the University of Michigan Rogel Cancer Center was initiated and developed over the years, as well as the importance of global engagement and patient advocacy.
The interview also explores the reasons behind the development of the two biotechnology companies Millendio Therapeutics and Vasaragen.
“Our charge is to stay one step ahead of this cellular arms race and to get the right drug to the right patient at the right time” stated Hammer.
Lauren Woolfe, Assistant Editor, and Commissioning Editor for the International Journal of Endocrine Oncology, commented, “This interview provides an insight into how one doctor is striving to provide the best care for patients with adrenal neoplasia’s, with Hammer exploring the past, present and future directions in endocrine oncology.”
View the Open Access articles online here:
About the International Journal of Endocrine Oncology
The International journal of Endocrine Oncology launched in 2014 and is a free-to-access quarterly forum for reviews, opinion, analysis and original research from international experts. The aim of the journal is to provide concise, up-to-date and clinically relevant content for the endocrine oncology community through online publication and our partnership with Oncology Central (www.oncology-central.com).
About Future Science Group (FSG)
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.